Toripalimab

Generic Name
Toripalimab
Brand Names
Loqtorzi
Drug Type
Biotech
Chemical Formula
-
CAS Number
1924598-82-2
Unique Ingredient Identifier
8JXN261VVA
Background

Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).

Indication

⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌(NPC)。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌(UC)。⑷用于食管鳞癌一线治疗。

Associated Conditions
-
Associated Therapies
-

Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

First Posted Date
2020-08-24
Last Posted Date
2020-08-24
Lead Sponsor
Fudan University
Target Recruit Count
10
Registration Number
NCT04524884
Locations
🇨🇳

270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

First Posted Date
2020-08-18
Last Posted Date
2021-07-30
Lead Sponsor
Fudan University
Target Recruit Count
126
Registration Number
NCT04517214
Locations
🇨🇳

Xiaomin Ou, Shanghai, China

A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors

First Posted Date
2020-07-22
Last Posted Date
2022-12-12
Lead Sponsor
Eucure (Beijing) Biopharma Co., Ltd
Target Recruit Count
26
Registration Number
NCT04481009
Locations
🇦🇺

Linear Clinical Research, Nedlands, Western Australia, Australia

Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients

First Posted Date
2020-07-16
Last Posted Date
2023-11-22
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
20
Registration Number
NCT04473716
Locations
🇨🇳

Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

First Posted Date
2020-07-15
Last Posted Date
2020-07-15
Lead Sponsor
Fudan University
Target Recruit Count
31
Registration Number
NCT04472806
Locations
🇨🇳

Zhiguo Luo, Shanghai, Shanghai, China

Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma

First Posted Date
2020-06-23
Last Posted Date
2020-06-23
Lead Sponsor
China Medical University, China
Target Recruit Count
44
Registration Number
NCT04443036
Locations
🇨🇳

The First Hospital of China Medical University, Shenyang, Liaoning, China

Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer

First Posted Date
2020-06-18
Last Posted Date
2020-06-26
Lead Sponsor
RenJi Hospital
Target Recruit Count
20
Registration Number
NCT04437212
Locations
🇨🇳

Renji Hospital, Shanghai, Shanghai, China

Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2020-06-05
Last Posted Date
2022-11-28
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
170
Registration Number
NCT04418648
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guang Zhou, China

Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients

First Posted Date
2020-06-05
Last Posted Date
2024-05-21
Lead Sponsor
Fudan University
Target Recruit Count
70
Registration Number
NCT04418154
Locations
🇨🇳

Shanghai Cancer Center, Fudan University, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath